<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01820559</url>
  </required_header>
  <id_info>
    <org_study_id>BIA-2093-209</org_study_id>
    <nct_id>NCT01820559</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Eslicarbazepine Acetate as Preventive Therapy for Subjects With Migraine</brief_title>
  <official_title>Efficacy and Safety of Eslicarbazepine Acetate as Preventive Therapy for Subjects With Migraine: a Doubleblind,Randomised, Placebo-controlled, Parallel-group, Multicentre Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bial - Portela C S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bial - Portela C S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This was a multinational, randomised, double-blind, placebo-controlled, parallel-group study
      to evaluate the efficacy, safety, and tolerability of multiple doses of ESL as prophylactic
      treatment in subjects with migraine with or without aura. Subjects were randomised in a 1:1:1
      ratio to receive placebo, ESL 800 mg/day once daily (QD), or ESL 1200 mg/day QD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study consisted of a Screening Period of 2 to 4 weeks, a 4-week placebo Baseline Period,
      a 2-week Titration Period, a 12-week Maintenance Period, and a 4-week Follow-up Period.
      During the entire study the subjects had a diary to document the occurrence, duration, and
      intensity of headaches, the occurrence or not of aura and its nature, as well as other
      related symptoms, and the use of study medication and acute medication.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute Change From Baseline in the Frequency of Migraine Attacks</measure>
    <time_frame>4 weeks</time_frame>
    <description>The primary efficacy variable was the absolute change from baseline in the frequency of migraine attacks standardised to 4 weeks in the Maintenance Period, as recorded in the subject diary. If there were less than 24 h between the end of 1 migraine event and the start of the next event, these 2 events were considered to belong to 1 migraine attack. There had to be a minimum of 24 h of freedom from headache, pain, and symptoms of migraine between attacks recorded in the subject diary to be considered as more than 1 attack of migraine for statistical analysis.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">452</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>ESL 1200 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>eslicarbazepine acetate 1200 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ESL 800 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>eslicarbazepine acetate 800 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablets</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Sugar pills</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ESL 1200 mg</intervention_name>
    <description>Eslicarbazepine acetate was supplied in 400-mg and 600-mg tablets and was administered with a dose of 800 or 1200 mg QD in the evening by the oral route.</description>
    <arm_group_label>ESL 1200 mg</arm_group_label>
    <other_name>Eslicarbazepine acetate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ESL 800 mg</intervention_name>
    <description>Eslicarbazepine acetate was supplied in 400-mg and 600-mg tablets and was administered with a dose of 800 or 1200 mg QD in the evening by the oral route.</description>
    <arm_group_label>ESL 800 mg</arm_group_label>
    <other_name>Eslicarbazepine acetate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women or men, 18 years of age or older (according to Amendment #1 for Czech Republic
             [24 Mar 2009]: 18 to 65 years of age).

          -  Diagnosis (established prior to 50 years of age) of migraine headaches for at least 1
             year, and a well-documented history of migraine headaches with or without aura
             according to the criteria of the IHS (see Section 3.5.6.1) for at least 3 months
             (according to Amendment #1 for Czech Republic [24 Mar 2009]: for at least 3 months
             with at least 3 migraine attacks per month in each of these 3 months).

          -  At least 2 (according to Amendment #1 for Czech Republic [24 Mar 2009]: at least 3)
             (and no more than 10) well-defined migraine headache attacks per month, with at least
             24 h of freedom from headaches and other symptoms of migraine between attacks.

          -  Able to distinguish the migraine headache attacks from other types of common headaches
             (tension-type headaches, sinus-related headaches, etc.).

          -  Not taking any prophylactic migraine therapies for at least 2 weeks prior to Baseline
             Visit (V2). Flunarizine had to be discontinued at least 4 weeks prior to V2.

          -  Able and willing to provide written informed consent to participate in the study after
             having the opportunity to review the Subject Information Sheet and Informed Consent
             Form (ICF).

          -  Able and willing to comply with all study requirements, in the judgment of the
             investigator.

          -  Women were surgically sterile (i.e. bilateral tubal ligation, bilateral oophorectomy,
             or hysterectomy), or at least 2 years postmenopausal or, if of childbearing potential,
             were sexually abstinent or agreed to use medically acceptable non-hormonal methods of
             contraception (see Section 3.3.3). (According to Amendment #1 for Czech Republic [24
             Mar 2009]: Women were sexually abstinent or agreed to use a double-barrier method of
             contraception. Hormonal contraceptives were not acceptable as a contraceptive method
             in this study. However, their intake was not forbidden throughout the study.)

        Exclusion Criteria:

          -  A known hypersensitivity to ESL or to other carboxamide derivatives (e.g.
             oxcarbazepine, carbamazepine), or to any of the excipients.

          -  Suspected or confirmed medication-overuse headache.

          -  More than 14 headache days (migraine or other headache types) per month in either of
             the 2 months prior to screening.

          -  Consistent or recurrent frequent headaches (i.e. ≥6 headache days a month) other than
             migraine headaches.

          -  Unable to discontinue medications primarily used for migraine prophylaxis that have
             been commonly used for other indications (tricyclic agents, divalproic acid,
             topiramate, etc.). A subject who received beta blockers or calcium channel blocker
             therapy for reasons other than migraine prophylaxis was eligible for inclusion,
             provided his/her dosing regimen had been stable for ≥2 months and was not expected to
             change during the course of the study.

          -  Using prohibited concomitant medication (see Section 3.5.5.2).

          -  A white blood cell (WBC) count &lt;2.5 * 109/L, neutrophil count &lt;1.5 * 109/L, sodium
             &lt;125 mmol/L, or alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥2
             times the upper limit of normal at V1 (Screening Visit), or any other clinically
             relevant laboratory abnormality that, in the investigator's opinion, could compromise
             the subject's safety.

          -  A creatinine clearance lower than 60 mL/min at screening.

          -  A second- or third-degree atrioventricular blockade not corrected with a pacemaker or
             any other clinically significant abnormality in the 12-lead electrocardiogram (ECG) as
             determined by the investigator.

          -  Pregnant or nursing women.

          -  A history of chronic alcohol or drug abuse or addiction within the last 2 years.

          -  A severe hepatic, renal, respiratory, haematological, or immunologic illness, unstable
             cardiovascular disease, or any other medical or psychiatric condition that, in the
             judgment of the investigator, made the subject inappropriate for entry into this
             study.

          -  Received an investigational drug (or a medical device) within 3 months of screening or
             was currently participating in another study of an investigational drug (or medical
             device).

          -  An employee of the investigator or study centre, with direct involvement in the
             proposed study or other studies under the direction of that investigator or study
             centre, or was a family member of the employees or the investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patricio Soares-da-Silva, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>BIAL - Portela &amp; Ca. SA</affiliation>
  </overall_official>
  <removed_countries>
    <country>Portugal</country>
  </removed_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 26, 2013</study_first_submitted>
  <study_first_submitted_qc>March 26, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 29, 2013</study_first_posted>
  <results_first_submitted>April 5, 2013</results_first_submitted>
  <results_first_submitted_qc>April 5, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 24, 2013</results_first_posted>
  <last_update_submitted>April 5, 2013</last_update_submitted>
  <last_update_submitted_qc>April 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 24, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>migraine; ESL; eslicarbazepine acetate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eslicarbazepine acetate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo tablets
Placebo : Tablets</description>
        </group>
        <group group_id="P2">
          <title>ESL 800 mg</title>
          <description>eslicarbazepine acetate 800 mg
ESL 800 mg :</description>
        </group>
        <group group_id="P3">
          <title>ESL 1200 mg</title>
          <description>eslicarbazepine acetate 1200 mg
ESL 1200 mg :</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="136"/>
                <participants group_id="P2" count="135"/>
                <participants group_id="P3" count="139"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Randomized and Treated</title>
              <participants_list>
                <participants group_id="P1" count="136"/>
                <participants group_id="P2" count="135"/>
                <participants group_id="P3" count="139"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Tutration Period</title>
              <participants_list>
                <participants group_id="P1" count="130"/>
                <participants group_id="P2" count="134"/>
                <participants group_id="P3" count="131"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Entered Maintenance Period</title>
              <participants_list>
                <participants group_id="P1" count="129"/>
                <participants group_id="P2" count="133"/>
                <participants group_id="P3" count="129"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Maintenance Period</title>
              <participants_list>
                <participants group_id="P1" count="122"/>
                <participants group_id="P2" count="123"/>
                <participants group_id="P3" count="110"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="122"/>
                <participants group_id="P2" count="122"/>
                <participants group_id="P3" count="110"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="29"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject's non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>At sponsor request</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo tablets
Placebo : Tablets</description>
        </group>
        <group group_id="B2">
          <title>ESL 800 mg</title>
          <description>eslicarbazepine acetate 800 mg
ESL 800 mg :</description>
        </group>
        <group group_id="B3">
          <title>ESL 1200 mg</title>
          <description>eslicarbazepine acetate 1200 mg
ESL 1200 mg :</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="136"/>
            <count group_id="B2" value="135"/>
            <count group_id="B3" value="139"/>
            <count group_id="B4" value="410"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="135"/>
                    <measurement group_id="B2" value="135"/>
                    <measurement group_id="B3" value="136"/>
                    <measurement group_id="B4" value="406"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="121"/>
                    <measurement group_id="B2" value="114"/>
                    <measurement group_id="B3" value="111"/>
                    <measurement group_id="B4" value="346"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Absolute Change From Baseline in the Frequency of Migraine Attacks</title>
        <description>The primary efficacy variable was the absolute change from baseline in the frequency of migraine attacks standardised to 4 weeks in the Maintenance Period, as recorded in the subject diary. If there were less than 24 h between the end of 1 migraine event and the start of the next event, these 2 events were considered to belong to 1 migraine attack. There had to be a minimum of 24 h of freedom from headache, pain, and symptoms of migraine between attacks recorded in the subject diary to be considered as more than 1 attack of migraine for statistical analysis.</description>
        <time_frame>4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablets
Placebo : Tablets</description>
          </group>
          <group group_id="O2">
            <title>ESL 800 mg</title>
            <description>eslicarbazepine acetate 800 mg
ESL 800 mg :</description>
          </group>
          <group group_id="O3">
            <title>ESL 1200 mg</title>
            <description>eslicarbazepine acetate 1200 mg
ESL 1200 mg :</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in the Frequency of Migraine Attacks</title>
          <description>The primary efficacy variable was the absolute change from baseline in the frequency of migraine attacks standardised to 4 weeks in the Maintenance Period, as recorded in the subject diary. If there were less than 24 h between the end of 1 migraine event and the start of the next event, these 2 events were considered to belong to 1 migraine attack. There had to be a minimum of 24 h of freedom from headache, pain, and symptoms of migraine between attacks recorded in the subject diary to be considered as more than 1 attack of migraine for statistical analysis.</description>
          <units>number of migraine attacks/participant</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
                <count group_id="O2" value="134"/>
                <count group_id="O3" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="0.1429"/>
                    <measurement group_id="O2" value="-1.0" spread="0.1428"/>
                    <measurement group_id="O3" value="-1.0" spread="0.1416"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Treatment-emergent adverse events(TEAEs) were evaluated throughout the study TEAEs, i.e. those Adverse Events (AEs) starting after the first dose intake until 28 days after the last dose, have been summarised by SOC and PT</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo tablets
Placebo : Tablets</description>
        </group>
        <group group_id="E2">
          <title>ESL 800 mg</title>
          <description>eslicarbazepine acetate 800 mg
ESL 800 mg :</description>
        </group>
        <group group_id="E3">
          <title>ESL 1200 mg</title>
          <description>eslicarbazepine acetate 1200 mg
ESL 1200 mg :</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>VENTRICULAR ARRHYTHMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>VIRAL INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>STATUS MIGRAINOSUS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>ADJUSTMENT DISORDER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="67" subjects_at_risk="135"/>
                <counts group_id="E3" subjects_affected="74" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="136"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="135"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="135"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="136"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="135"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="136"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="135"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="136"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="135"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="135"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="135"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="135"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Face oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="136"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="135"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="135"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="135"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="135"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="136"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="136"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="135"/>
                <counts group_id="E3" events="14" subjects_affected="14" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="135"/>
                <counts group_id="E3" events="13" subjects_affected="13" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="136"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="135"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Tension headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Status migrainosus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="135"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="136"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="135"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Head of Clinical Research Section</name_or_title>
      <organization>BIAL - Portela &amp; Ca, SA</organization>
      <phone>351 22 986 6100</phone>
      <email>clinical.trials@bial.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

